VTD indicates bortezomib, thalidomide, and dexamethasone; CTD, carfilzomib, thalidomide, and dexamethasone RVD, lenalidomide, bortezomib, and dexamethasone; CRD, carfilzomib, lenalidomide, and dexamethasone; CyBorD, cyclophosphamide, bortezomib, and dexamethasone; VD, bortezomib and dexamethasone; dara, daratumumab; VMD, bortezomib, melphalan, and dexamethasone; PR, partial response; VGPR, very good partial response; CR, complete response; nCR, near complete response; and NR, not reported.